Who Funds Europe’s AI Roll-Ups?

Last week we portrayed the landscape of Europe’s emerging AI roll-ups by sector; this week we look into some of the sources of capital supporting it. 

Traditionally, venture capital backed the software, while private equity backed the roll-up. AI roll-ups are blurring this line, drawing in a unique mix of top early-stage VCs and growth funds.

Global venture funds are taking strong positions in the category. General Catalyst has committed $1.5bn to its Creation strategy, with Dwelly and Integral the fund’s most visible investments in Europe. The funds sit in a separate vehicle to their core seed to growth fund, and are earmarked precisely for the acquisition of conventional services businesses that are being transformed by AI. Other active global funds in this space include Google Ventures (GV), which has backed Buena and Lawhive, and Insight Partners, which led the seed into Theo, the Berlin property management roll-up.

We are now seeing the emergence of funds in Europe created specifically for this thesis. Tenet Capital launched in Berlin in February 2026, purpose-built for the AI roll-up category, with an €80m target and writing €5m cheques at the inception stage. They have already announced the backing of medical tax firm roll-up, Taxforce. Alongside them, funds like OpenOcean are actively building focused positions within the space, having invested in the short-term rental consolidator Arbio and the property management platform, Levels.

Large European funds leading the charge include Eurazeo -  backing Arbio, Avi Medical and Archipel and Balderton Capital backing Avi Medical and Lawhive. EQT Growth co-led Dwelly's Series B. In Germany, the same four names recur across the same four companies: Tengelmann Ventures, Cherry Ventures, Vorwerk Ventures and Aven Capital Partners are supporting Averia, Aretea, IX Gruppe and Habanero. Elsewhere, Strada Partners took a majority in Numeris, Alpera Partners backs Archipel, Swiss PE Growth investors Partners Group led Afileon, Warsaw Equity Group led Jutro Medical, and Discovery Ventures sits behind DAP and Habanero.

To realize their mission, AI roll-ups need both equity to develop the AI-native core, plus debt to fund the acquisitions, while minimizing shareholder dilution. Initial acquisitions are funded through a mix of equity, seller notes (deferred payments), and earnouts (performance-contingent consideration). Some platforms also offer sellers equity in the group rather than a full cash exit, as compared to a private equity bid that often cashes the owner out entirely. This minimizes the cash required when each deal is closed, and keeps the seller directly exposed to the outcome.

Debt is typically raised once the first businesses have been integrated and an operating history exists. By that point there are acquired cash flows, a repeatable integration process and evidence of margin improvement, all of which can be underwritten. Looking at where European AI roll-ups have actually raised, the debt has come from four types of lender: venture and growth debt funds, sector-specialist credit funds, commercial banks, and private markets capital at the larger end. Facilities are typically sized against asset-level or group EBITDA rather than ARR. Venture debt and growth debt funds tend to serve companies with revenue traction and strong equity backing but limited group profitability, while private credit and direct lending funds come in at greater scale once there is EBITDA generation, and take on higher leverage. Commercial banks lend where the acquired businesses are conventionally profitable.

This hybrid approach is evident in the larger rounds shaping the European AI roll up landscape: Dwelly's $170m Series B was structured as $95m in equity, and $75m in debt led by Trinity Capital, following a February round that paired £32m of equity with a £37m Trinity facility. Patient21 raised €100m at its Series C on roughly 70% equity and 30% debt, with the debt coming from IPF Partners, a healthcare specialist lender. Jutro Medical's €24m Series A extension included debt from mBank and Orbit Capital, while Arbio's $50m round in February 2026 included $14m of debt from Atempo Growth. HealthHero has taken its facility with Claret Capital to €30m. 

At EIV, we are supporting founders of AI roll ups to raise both equity and debt funding. If you are building one, we would love to hear from you.